Steven Nissen - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Steven Nissen's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Steven Nissen
Verified
Contributor, Annals of Internal Medicine
Beats
Nothing.
Content
By Steven Nissen| HCP Live Verified Author(s):Fact checked by:Steve Nissen, MD, discusses the phase 2 ALPACA trial and how it informs the potential of lepodisiran for lowering Lp(a). The ALPACA trial demonstrated lepodisiran, a long-acting small interfering RNA therapy, significantly and durably reduces lipoprotein(a) [Lp(a)] levels, with effects lasting up to 18 months.
By Steven Nissen, Qiuqing Wang, Stephen Nicholls Verified, Ann Marie Navar| JAMA: Journal of the American Medical Association Verified Zerlasiran for the Treatment of Atherosclerotic Cardiovascular Disease—ReplyZerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a) Steven E. Nissen, MD; Qiuqing Wang, MS; Stephen J. Nicholls, MBBS, PhD; Ann Marie Navar, MD, PhD; Kausik K. Ray, MD, MPhil; Gregory G. Schwartz, MD, PhD; Michael Szarek, PhD; Erik S. G. Stroes, MD, PhD; Roland Troquay, MD; Jannick A. N. Dorresteijn, MD, PhD; Henry Fok, MBBS, PhD; David A.
By Steven Nissen| HCP Live Verified Author(s):Fact checked by:Steve Nissen, MD, discusses the phase 2 ALPACA trial and how it informs the potential of lepodisiran for lowering Lp(a). The ALPACA trial demonstrated lepodisiran, a long-acting small interfering RNA therapy, significantly and durably reduces lipoprotein(a) [Lp(a)] levels, with effects lasting up to 18 months.
Company Info
Annals of Internal Medicine